

In this report, “Innovus Pharmaceuticals,” “Innovus Pharma,” “the Company,” “we,” “us” and “our” refer to Innovus Pharmaceuticals, Inc., and/or one or more of our wholly-owned subsidiaries, unless the context otherwise provides. Innovus Pharma® is a registered service mark of Innovus Pharmaceuticals, Inc.

Item 7.01 – Regulation FD Disclosure

Item 8.01 – Other Events

On March 22, 2017, the Company issued a press release reporting that the Company has repaid all of its outstanding convertible notes. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 -- Financial Statements and Exhibits

(d) Exhibits

Exhibit Number	Description
99.1	Press release issued March 22, 2017, reporting that the Company has repaid all of its outstanding convertible notes.

SIGNATURES

Pursuant to
the
requirements
of the
Securities
Exchange
Act of 1934,
the
Registrant
has duly
caused this
Report to be
signed on its
behalf by the
undersigned
hereunto duly
authorized.

INNOVUS PHARMACEUTICALS, INC

Date: March 22, 2017 By: /s/ ROBERT E. HOFFMAN
Robert E. Hoffman
Executive Vice President, Chief Financial Officer

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press release issued March 22, 2017, reporting that the Company has repaid all of its outstanding convertible notes.